NASDAQ: PMN - ProMIS Neurosciences, Inc.

Rentabilität für sechs Monate: -43.99%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan ProMIS Neurosciences, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.

weitere details
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2007-07-17
ISIN CA74346M4065
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.promisneurosciences.com
Цена ао 0.73
Preisänderung pro Tag: +0.0143% (0.7)
Preisänderung pro Woche: +9.39% (0.64)
Preisänderung pro Monat: -9.08% (0.77)
Preisänderung über 3 Monate: -22.21% (0.9)
Preisänderung über sechs Monate: -43.99% (1.25)
Preisänderung pro Jahr: -63.35% (1.91)
Preisänderung über 3 Jahre: +600.1% (0.1)
Preisänderung über 5 Jahre: +400.07% (0.14)
Preisänderung seit Jahresbeginn: -23.9% (0.92)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 2.24 7
P/E 0 0
EV/EBITDA 0.2826 10
Gesamt: 4.63

Effizienz

Name Bedeutung Grad
ROA, % -73.22 0
ROE, % -265.68 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 212.45 10
Rentabilität EPS, % 8.71 2
Gesamt: 6.4
Weitere Details

Institutionen Volumen Aktie, %
Sphera Funds Management Ltd. 1834042 9.67
Ally Bridge Group (NY) LLC 1066674 5.63
Affinity Asset Advisors, LLC 265958 1.4
Northeast Financial Consultants Inc 100000 0.53
IEQ CAPITAL, LLC 30799 0.16
Fiduciary Trust Company (MA) 20008 0.11
Kingsview Wealth Management, LLC 11100 0.06
Claret Asset Management Corp 10830 0.06
UBS Group AG 5926 0.03
Bank of America Corporation 1666 0.01



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Neil R. Cashman M.D. Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director 333.8k 1952 (73 Jahr)
Mr. Gavin T. Malenfant Chief Operating Officer 413.49k 1964 (61 Jahr)
Mr. Daniel E. Geffken M.B.A. Chief Financial Officer 89.99k 1957 (68 Jahre)
Dr. Johanne Kaplan Ph.D. Chief Development Officer 263.07k 1960 (65 Jahre)
Dr. Ernest D. Bush Ph.D. Head of Pharmacology/Toxicology & Senior Consultant N/A
Dr. David Wishart Ph.D. Chief Physics Officer N/A
Mr. Dennis Chen Ph.D. Head of Manufacturing & Senior Consultant N/A
Dr. Larry Douglas Altstiel M.D., Ph.D. Chief Medical Officer N/A 1950 (75 Jahre)
Mr. Neil K. Warma M.B.A. President, Interim CEO & Director 40k 1963 (62 Jahr)
Mr. Eugene W. Williams Co-Founder & Chairman 1959 (66 Jahre)

Adresse: Canada, Toronto. ON MS E, 1920 Yonge Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.promisneurosciences.com